DEMOGRAPHIC PROFILE, SUBSTANCE USE TRENDS AND ASSOCIATED PSYCHOTIC DISORDERS AMONG VETERANS WITH MENTAL HEALTH CONDITIONS: A RETROSPECTIVE COHORT STUDY OF US VETERANS

Jason Obermann, MD*, Krishna Divadeenam, MD*, Alexandra V. Flynn, MD, MS, PhD**, COL (Ret.)

Hemant Thakur, MD*, Vikas Singh, MD*, Rishi Sharma, MD, MHSA*, Thomas Wiegmann, MD*,
Varun Boinpelly, MS*, Kenneth Grasing, MD, Mukut Sharma, PhD*, Ram Sharma PhD., MHSA***

*Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States of America
** Robert J. Dole Veterans Affairs Medical Center, Wichita, Kansas, United States of America

Abstract

Background: Amphetamine and other substances induced psychotic disorder and associated suicidal risk among hospitalized US veterans is not clear.

Aims: To understand the demographic profile, substance use trends, psychotic disorders and suicide attempts in veterans hospitalized with acute Mental Health Conditions (MHC).

Methods: Veterans Affairs Informatics and Computing Infrastructure Database and ICD codes were used to identify veterans hospitalized with MHC diagnosis between 10/1/1999 and 02/27/2022. Laboratory records were used to determine types of substances used, hospitalization frequency, all-cause mortality, suicide attempts and suicide outcomes. SAS was used for statistical analysis.

Results: Psychosis, manic-bipolar and PTSD were common diagnosis among veterans with MHC. Psychosis was comparatively less common among males above 50 years of age, but was prevalent among Hispanics. Substances use was significantly higher among veterans with MHC. Amphetamines were most used substance, followed by cannabis codeine, morphine, cocaine, barbiturates, fentanyl, and PCP. Amphetamine induced psychotic disorder persisted in 22.28%, whereas other substance induced psychotic disorder persisted in 77.72% of veterans hospitalized with MHC. Psychosis was associated with higher rates of hospitalization, suicide attempts, and suicide death.

Conclusions: Amphetamine was most used substance associated with higher rates of psychotic disorders, hospitalization, suicide attempts, and death among US Veterans with MHC. ASEAN Journal of Psychiatry, Vol. 25 (7) July, 2024; I-11.

Keywords: Psychosis; Schizophrenia; Psychotic Disorders; Suicide Attempts; Mortality

Introduction

Substance use is common and often presents with psychotic symptoms. In fact, 7%-25% of first episode of psychosis is precipitated by substance use [1]. Conversion rates from Substance-Induced Psychotic Disorders (SIPD) to schizophrenia, a Primary Psychotic Disorder (PPD) varies with type of substance used. Psychotic disorder rates are highest (34%-50%) among cannabis users and lowest (5%) among alcohol users [2-6]. Use of methamphetamine can induce Amphetamine Induced Psychotic Disorder (AIPD) as defined
by the Diagnostic criteria in the fifth edition (DSM-5) of the diagnostic and statistical manual of mental disorders. There are an estimated 27 million amphetamine users worldwide and approximately 2.3% of the North American population between the ages of 15-64 have used amphetamines in the past one year [7]. It is estimated that as many as 40% of amphetamine users will experience AIPD [2].

Established risk factors for AIPD include a history of PPD, schizotypal and antisocial personality disorders, family history of mental illness, and methamphetamine dependence [8]. Conversion rates from AIPD to PPD are in the range of 19%-40% [2,3,6,9,10]. There are many subject specific factors that contribute in conversion from AIPD/SIPD to PPD including a family history of schizophrenia in first degree relative, male gender, urban living, extended duration of untreated psychosis, continued substance abuse after index psychotic episode, first episode of substance induced psychosis at younger age, and a pre-existing diagnosis of either a substance use disorder, personality disorder (specifically schizotypal and antisocial), or an eating disorder prior to the index psychotic episode [2,6,11]. Moreover, conversions may occur rapidly as shown in one study that 50% of conversions from AIPD/SIPD to schizophrenia (PPD) occur within 3.1 years of the index substance induced psychotic episode [6].

Treatment for SIPD/AIPD is evolving [12]. It is a recent diagnostic addition in the DSM-IV and presently under significant scrutiny [13]. Subjects presenting psychotic behavior in the context of substance abuse are often diagnosed with SIPD/AIPD and providers often neglect to consider the presence of an underlying primary psychotic disorder. Confirmation bias is an issue and that may delay in anti-psychotic treatment or in giving an inaccurate advice to subjects that the symptoms will resolve with cessation of drugs alone. This may lead to suboptimal treatment of subjects with AIPD/SIPD [12]. Additionally, the AIPD/SIPD subjects population is often excluded from clinical trials resulting in a paucity of data to guide clinicians for better management of subjects suffering from AIPD/SIPD [14,15]. This is alarming because they suffer from severe symptoms, higher rates of hospitalization, and are more likely to attempt suicide than methamphetamine users without psychotic features [16]. Furthermore, younger AIPD/SIPD subjects with an average age of 30.4 years and a history of requiring hospitalization have unusually high mortality rates (>8%) within 6 years of hospitalization [9]. This is of particular concern because the suicide rate is higher among veterans as compared to the general population and that suicide rate is doubled among veterans with a diagnosis of a substance use disorder [17,18]. Despite alarmingly high rates of mortality among subjects population with AIPD/SIPD, treatment is often delayed resulting in prolonged periods of psychosis and a poor prognosis [5]. To date there are only few studies conducted in the veteran population. Given the elevated risk of suicide within the veteran population this study was undertaken to understand the demographic profile, incidence of mental disorders, substance use trends and associated psychotic disorders among subjects with mental illness admitted to any VA Medical Center within USA.

**Materials and Methods**

**Data base and study design**

Veterans’ Health Administration’s Corporate Data Warehouse (VHA-CDW) uses a unique identifier to identify veterans across treatment episodes at more than 1,400 VHA centers organized under 21 Veterans Integrated Service Networks (VISN). The VHA-CDW database contains diagnostic, laboratory, pharmacy, and other procedure related data from various sources in the electronic health record. The VHA-CDW data and the VA Informatics and Computing Infrastructure (VINCI) workspace have been used widely for numerous clinical studies of importance [19]. In this retrospective cohort study, we used VHA-CDW and VINCI to extract existing data.

**Study population**

Mental health conditions (MHC) included Psychosis, Manic-bipolar disorders, PTSD, schizophrenia, depression and TBI defined by International Statistical Classification of Diseases and Related Health Problems, Ninth and Tenth Revision (ICD-9, ICD-10) codes. Study population consisted of 156,435 veterans with MHC diagnosis (Group 2) between October 1, 1999 and February 27, 2022. We randomly selected a total of 156,189 cases of admissions of
similar gender, race, and age without any MHC diagnosis (Group 1). The final study groups comprised of cases admitted to hospital with and without MHC balanced for confounding factors such as age, race, sex, smoking and Type 2 diabetes during the study period.

**Data analysis**

We used the date of first admission (first occurrence in the data set) during the study period of 10/1/1999 through 02/27/2022 as the index time point to differentiate pre-existing and new events data. We used a combination of standard SQL accessible files for ICD, lab, or drugs and free text medical and administrative record searches to collect information on conditions, medications, and procedures.

Data were used as categorical variables and analyzed by standard frequency tables (chi sq and Odds ratios) using SAS (Guide 8.2). Continuous variables such as age are shown as Means (±SD), Odds ratios (OR) were also calculated. A Logistics procedure was used to initially evaluate associations of multiple variables with the various outcome variables. A greedy neighbor (nearest neighbor) procedure was used as given by SAS for the evaluation of all-cause mortality (death).

Principal outcomes were designated as number of hospital admissions (1-9 or >10), suicide rate (attempts/demise) and all-cause mortality among two groups. Frequencies, means, and Odds ratios were calculated and are reported in the tables and a p-value of <0.01 was deemed significant.

**Ethics approval**

This study (IRBNet #1663414) was approved by the Kansas City VA Medical Center (FWA 00001481) Institutional Review Board (IORG 0000081) on March 17, 2022, and complies with the declaration of Helsinki.

**Results**

**Demographic characteristics of study population**

We categorized demographics into age groups (18-25, 26-35, 36-50, 51-65 and >65 years), race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, white, White Not of Hispanic origin and declined to answer/unknown), ethnicity (Hispanic/Latino, non-Hispanic/Latino and unknown/declined to answer) and marital status (single/never married, married, separated/ divorced, widow/widower/widowed and unknown/missing).

As shown in Table 1, age had a measurable effect on prevalence of mental illness. The proportion of subjects with mental illness diagnosis increased in the age groups up to 50 years and then subsequently declined in the age groups of >50 years subjects. In general, older subjects did better (OR=0.81, p<0.001).

**Table 1. Demographic characteristics of study population.**

<table>
<thead>
<tr>
<th>Age groups, number (%)</th>
<th>Group 1, subjects with no Mental Health Conditions (MHC) diagnosis N=156,189</th>
<th>Group 2 subjects with MHC diagnosis N=156,435</th>
<th>p-value Group 2 vs Group 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-25 years</td>
<td>125 (0.08%)</td>
<td>172 (0.11%)</td>
<td>-</td>
</tr>
<tr>
<td>26-35 years</td>
<td>6,388 (4.09%)</td>
<td>9,730 (6.22%)</td>
<td>-</td>
</tr>
<tr>
<td>36-50 years</td>
<td>24,537 (15.71%)</td>
<td>33,555 (21.45%)</td>
<td>-</td>
</tr>
<tr>
<td>51-65 years</td>
<td>80,422 (51.49%)</td>
<td>74,760 (47.79%)</td>
<td>-</td>
</tr>
<tr>
<td>Above 65 years</td>
<td>44,701 (28.62%)</td>
<td>38,201 (24.42%)</td>
<td>-</td>
</tr>
<tr>
<td>≥ 50 years</td>
<td>44707 (28.62%)</td>
<td>38,178 (24.42%)</td>
<td>-</td>
</tr>
<tr>
<td>&lt;50 years</td>
<td>111,483 (71.38%)</td>
<td>118257 (75.58%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

| Gender (sex), number (%) | | |
|--------------------------|--------------------------|
| Male                     | 147,769 (94.61%)         | 146572 (93.7%)       |
A great majority of subjects in the study were divorced or separated. About 18% were married and about 25% had never been married. All-cause mortality numbers were significantly less in the mental illness group as compared to the control group (OR=0.740, p<0.001). Distribution of various MHC diagnoses

As shown in Figure 1, psychosis, manic-bipolar and PTSD were most common (28%) followed by schizophrenia (9.83%) and depression (6.66%). TBI was uncommon at 2.4% of cases. Our analysis did not exclude any cases from any category where there was overlap as the primary condition could not always be identified.
Use of PCP was uncommon among these subjects.

**Primary and drug-induced psychosis among veterans with mental health conditions**

As shown in Table 3, out of 156,435 subjects with mental illness in this study, 43,979 (28%) subjects carried a diagnosis of psychosis of which majority 38,710 (88%) were non-substance users. Only 5,269 (12%) subjects with psychosis diagnosis used substances and out of those 1,174 subjects used amphetamine and 4,095 subjects used other substances including cannabis, codeine, morphine, cocaine, barbiturates, fentanyl, and PCP resulting in an Amphetamine Induced Psychotic Disorder (AIPD) rate of 22.28% and Substance abuse Psychotic Disorder (SIPD) rate of 77.72%.

**Frequency of hospitalization, suicide attempts and suicide death**

As shown in Table 4, frequency of hospitalization (>10 admissions) was significantly higher (p-value <0.001) in the study subjects with mental illness (Group 2, 52.9%), diagnosis as compared to subjects without any mental illness diagnosis (Group 1, 47.11%) with an OR=1.22. Similarly, suicide rate, suicide attempts and death was also significantly higher (p<0.0001) among subjects with mental illness (Group 2) as compared to subjects without any mental illness diagnosis (Group 1).

**Table 2. Substances use frequency among subjects with and without Mental Health Conditions (MHC) diagnosis.**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Group 1 no MHC 156189</th>
<th>Group 2 MHC 156435</th>
<th>Odds ratio Group 2 vs Group 1</th>
<th>p-value Group 2 vs Group 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug users N (%)</td>
<td>2134 (1.37%)</td>
<td>18,744 (11.98%)</td>
<td>11.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>453 (0.29%)</td>
<td>4179 (2.67%)</td>
<td>9.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>406 (0.26%)</td>
<td>1927 (1.23%)</td>
<td>4.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cannabis</td>
<td>359 (0.23%)</td>
<td>3617 (2.31%)</td>
<td>10.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cocaine</td>
<td>513 (0.33%)</td>
<td>2650 (1.69%)</td>
<td>5.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Codeine</td>
<td>222 (0.14%)</td>
<td>3051 (1.95%)</td>
<td>13.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>13 (0.01%)</td>
<td>750 (0.48%)</td>
<td>57.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Morphine</td>
<td>52 (0.03%)</td>
<td>1987 (1.27%)</td>
<td>38.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>PCP</td>
<td>116 (0.07%)</td>
<td>583 (0.37%)</td>
<td>5</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

**Note:** Numbers as (percent) of total subjects in Group1 (control) and Group 2 (MHC); p-value represents significance when compared Group 2 vs Group 1.
Discussion

Demographic characteristics of our study population demonstrated that mental illness diagnosis was less frequently associated with males than females (OR=0.85, p<0.001). These findings parallel global statistics. The age-standardized disability-adjusted life-years rate for mental disorders, prevalence and incidence rates of common mental disorders, specifically affective disorders, such as anxiety and depression, is greater in females than males [20,21]. We found that overall mortality was less common (OR=0.740, p<0.001) in mental illness group compared to control group. This correlates with the findings of the systematic analysis for the Global Burden of Disease Study 2019, which concluded that estimated years of life lost for mental disorders were low and do not reflect premature mortality in individuals with mental illness [20]. Veterans of Hispanic origins were more likely to carry a diagnosis of mental illness (OR=1.28, p<0.001). Our data and published reports suggest a need to do additional epigenetic and sociocultural research in the Hispanic population [22].

We found that substance abuse was significantly higher in the mental illness group (11.98%) compared to the control group (1.37%, OR=11.1). Co-occurring Substance Use Disorders (SUD) with Mental Disorders is a well-known phenomenon, frequently referred as a dual diagnosis, which is highly prevalent and represents a serious national health problem. Unfortunately, it is often under-diagnosed and therefore, poorly treated. In a nationally representative US sample, dually diagnosed adults are estimated to represent 17.8% of the 75.6 million adults diagnosed with SUD and mental disorder [23].

We observed a monumental increase in abuse of morphine (OR=38.6) and fentanyl (OR=57.9) by 48 and 42 times, respectively, among subjects with mental illness when compared with hospitalized adults without concurring mental illness. It is well known that a dual diagnosis is especially prevalent among adults with the Opioid Use Disorder (OUD) and that it increases the risk for morbidity and mortality. For instance, 24.5% of adults with OUD and recent mental illness in the past year and 29.6% of adults with OUD and serious mental

Table 3. Amphetamine-Induced Psychosis Disorder (AIPD) vs other Substances-Induced Psychosis Disorder (SIPD) among subjects diagnosed with psychosis.

<table>
<thead>
<tr>
<th>Measured outcome</th>
<th>Group 1 (no-MHC)</th>
<th>Group 2 MHC diagnosis</th>
<th>Odds ratio Group 2 vs Group 1</th>
<th>p-value Group 2 vs Group 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10 admissions</td>
<td>73,581 (47.11%)</td>
<td>81,419 (52.05%)</td>
<td>1.22</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Suicide rate</td>
<td>3,972 (2.54%)</td>
<td>58,012 (37.08%)</td>
<td>23.32</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Suicide Attempt</td>
<td>2,644 (1.69%)</td>
<td>43,035 (27.51%)</td>
<td>57.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Death by Suicide</td>
<td>1,328 (0.85%)</td>
<td>14,698 (9.40%)</td>
<td>38.6</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Note: Numbers as (percent) of total subjects in Group 1 (control) and Group 2 (MHC); p-value represents significance when compared Group 2 vs Group 1.

Table 4. Comparison of outcomes among subjects with and without MHC.

<table>
<thead>
<tr>
<th>Measured outcome</th>
<th>Group 1 (no-MHC)</th>
<th>Group 2 MHC diagnosis</th>
<th>Odds ratio Group 2 vs Group 1</th>
<th>p-value Group 2 vs Group 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterans with Psychosis DX N=43,979 (28.14%)</td>
<td>Non-substance users N=38,710 (88.01%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substance users, N=5,269 (11.98%)</td>
<td>Amphetamine users, N=1,174</td>
<td>Other substance users N=4,095</td>
<td>AIPD rate 22.28%</td>
<td>SIPD rate 77.72%</td>
</tr>
</tbody>
</table>

Note: Numbers as (percent) of total subjects in the category; AIPD and SIPD rate in % is calculated by dividing numbers of amphetamine and other substances users by the number of substance users with psychosis diagnosis.
illness reported receiving services for both mental health and substance use treatment [24]. This is alarming because opioid abuse in the US has reached an epidemic status. The alarming increase in fentanyl abuse found in our study corresponds with the current course of the US opioid crisis. Three main causes for the opioid epidemic are:

- Increase in prescription of opioids,
- Drug use, and
- Access to illicitly manufactured fentanyl.

Centers for disease control and prevention statistics estimated 500,000 opioid associated deaths between 1996 and 2019.

While death related to the opioid drug overdose started to decline in 2017, Fentanyl use associate deaths continue to increase [25].

Use of amphetamine among veterans with mental illness is higher than estimated use among 15-64 years old North American population. We detected that amphetamines (OR=9.4), cannabis (OR=10.5) and codeine (OR=13.9) abuse was 9.2 to 13.92 times more frequently noted in the MHC group. Moreover, amphetamine was the most frequently used substance (2.67%), followed by cannabis (2.3%), codeine, morphine, cocaine, barbiturates, fentanyl, and PCP in the mental illness group. Our findings correlate with both nation and worldwide trends, showing that synthetic drugs, represented by methamphetamine, have become the most abused drugs in the world and have surpassed traditional drugs of abuse (including opioids). The rates of stimulant use disorders, including methamphetamine, and stimulant-related overdose and mortality is steadily increasing in the USA [26-29].

We observed that Amphetamine Induced Psychotic Disorder (AIPD) presented in 22.28% whereas other Substance (cannabis, codeine, morphine, cocaine, barbiturates, fentanyl, and PCP) Induced Psychotic Disorder (SIPD) presented in 77.72%. Psychosis has been described in the medical literature as a well-known complication of long-term methamphetamine use since after the Word War II. Epidemiologic studies provide different opinions regarding the prevalence of AIPD [30]. One meta-analysis of seventeen studies showed a composite event rate of 36.5%. Overall, difference in prevalence of AIPD varies from 13% in the USA to 50% in Asia that can be explained by the potency and purity of methamphetamines used in different geographic locations [31].

The time elapsed from the initial substance use to developing AIPD varies from a few weeks to years. It is influenced by the frequency of consumption, dose of the substance, route of administration (intravenous, oral, inhalation), and individual vulnerability to psychosis. Early consumption of amphetamines initially induces psychotomimetic effects, to include euphoria, feelings of increased concentration and stimulation. Continuous use of methamphetamine induces pre-psychotic delusional moods followed by overt psychotic state manifesting with delusions and hallucinations [32].

In our study 11.98% of veteran-subjects with psychosis diagnosis used substance. Psychosis among amphetamine and other substance users presented at higher rate among subjects with mental illness. The most prevalent AIPD symptoms are persecutory delusion (82%), auditory hallucination (70.3%), and delusion of reference (57.7%), visual hallucination (44.1%), grandiosity delusion (39.6%) and jealousy delusion (26.1%). AIPD may be accompanied by severe violent behavior warranting clinical intervention to prevent harm to subjects and society. Tactile hallucinations are more so frequent among subjects using higher daily doses of the drug and frequently described as parasites crawling under subject’s skin (formication, “meth mites”).

Chronic methamphetamine use induces neuroinflammation, ischemia, oxidative stress, and direct neurotoxicity leading to degeneration processes. It may unmask or expedite the development of schizophrenia in first-degree relatives of subjects with schizophrenia, emphasizing the importance of differentiating AIPD from schizophrenia. Higher prevalence of visual and tactile hallucinations was reported among subjects with AIPD vs schizophrenia, while delusion patterns were similar in both groups. Subjects with AIPD have less “negative” psychotic symptoms (i.e., social withdrawal, blunted affect, disorganization, etc..) and similar levels of “positive” symptoms (i.e., hallucinations, paranoid delusions) compared with schizophrenic subjects [32,33].

The large number of drug reactions and side effects would be expected to lead to increased use of medical services and complications. Indeed, we found that a diagnosis of mental illness was significantly associated with higher...

Unfortunately, there are no FDA-approved medications for treating either AIPD or methamphetamine use disorder. Most medications evaluated for methamphetamine/amphetamine use disorder have not shown a statistically significant benefit. However, there is low-strength evidence that Methylphenidate may reduce amphetamine/methamphetamine use.

Numerous Randomized Controlled Trials (RCTs) investigated over 20 potential pharmacotherapies. Methylphenidate, Bupropion, Modafinil, and Naltrexone demonstrated limited evidence of benefit for reducing amphetamine use. Dexamphetamine has benefit on treatment retention, but not for reducing amphetamine use. Based on moderate strength evidence, antidepressants as a class, to include SSRIs, have not shown statistically significant effect on either abstinence or treatment retention [41,42].

Methamphetamine triggers neurotoxicity, oxidative change, neuroinflammation, induces cell death cascade, and degenerative loss of dopaminergic neurons in the brain, which contributes to the higher risks of developing Parkinsonism syndrome and Parkinson's disease itself among methamphetamine users [43]. Therefore, when treating AIPD, clinicians should keep in mind that these subjects are at increased risks of extrapyramidal movement complications, if treated with the first-generation antipsychotics, such as Haloperidol. Consequently, second-generation antipsychotics maybe a preferable class to address psychotic symptoms of AIPD. Subjects diagnosed with substance induced psychotic disorder require close follow up and treatment with psychotropic medications.

Conclusion

In conclusion, our results call for action to increase awareness among VHAs and general practicing clinicians to address the surge in amphetamine use and related mortality, seek evidence-based prevention strategies, and treatment interventions for the amphetamine use associated disorder including AIPD. Further research is urgently needed to identify successful public health approaches targeting Methamphetamine abuse epidemic and to develop effective clinical interventions and relapse prevention strategies.

Our findings underscore the importance of considering demographic factors such as age, gender, race, and service-related characteristics in
understanding the complex landscape of mental health among veterans. Furthermore, the link between substance use and psychotic disorders among this population highlights the need for integrated screening, prevention, and treatment approaches that address both mental health and substance use disorders concurrently.

Limitations of our study include

- False-positive or false-negative Urine Drug Screens (UDS) for amphetamine might have occurred in small number of subjects.
- UDS amphetamines detection could have included prescription stimulants for ADHD, narcolepsy, off-label treatment for major depressive disorder, weight-loss medication, etc., and
- Initial diagnosis of AIPD could have overlapped with unmasked symptoms of first onset of psychosis, schizophrenia, or schizophrenia-like presentation secondary to poly substance use, including highly potent synthetic cannabinoids.

Acknowledgements

This work was supported by the resources from both Kansas City VA medical center and Midwest Veterans biomedical research foundation.

Disclosures

The contents of this article are those of authors and do not necessarily reflect the position and policy of the Department of Veterans Affairs. All authors’ participants have given consent for their data to be used in the research. The data that support the findings of this study are available from the corresponding author, (RS), upon reasonable request.

References

7. Substance abuse and mental health services administration. 2021.
14. Weibell MA, ten Velden Hegelstad W, Johannessen JO. Substance-induced psychosis:


Demographic Profile, Substance use Trends and Associated Psychotic Disorders among Veterans with Mental Health Conditions: A Retrospective Cohort Study of US Veterans

Corresponding author: Ram Sharma, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States of America

E-mail: Ram.Sharma2@va.gov

Received: 11 June 2024, Manuscript No. AJOPY-24-138679; Editor assigned: 14 June 2024, PreQC No. AJOPY-24-138679 (PQ); Reviewed: 28 June 2024, QC No. AJOPY-24-138679; Revised: 05 July 2024, Manuscript No. AJOPY-24-138679 (R); Published: 12 July 2024, DOI: 10.54615/2231-7805.47358.